OncLive TV

Dr. Venook on Evolving Treatment Strategies in CRC

July 22nd 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how treatment strategies have evolved for patients with colorectal cancer.

Dr. Udit Verma on Managing Regorafenib Side Effects in CRC

July 22nd 2016

Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer

July 22nd 2016

Dr. Bekaii-Saab on Dosing Strategies With Regorafenib in CRC

July 22nd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses dosing strategies with regorafenib (Stivarga) in patients with colorectal cancer (CRC).

Dr. Haseebuddin on PD-1 Expression on Monocytes in RCC

July 21st 2016

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discusses the overall significance of a study examining an elevated preoperative classical monocyte PD-1 mean fluorescence intensity level in patients with clear cell renal cell carcinoma.

Dr. Dicato on Agents to Treat Thrombocytopenia for Patients With Cancer

July 21st 2016

Mario Dicato, MD, Hematology-Oncology Service, Centre Hospitalier de Luxembourg, discusses 3 agents used for the treatment or reduction of thrombocytopenia for patients with cancer.

Dr. Strosberg on Pasireotide for Neuroendocrine Tumors

July 20th 2016

Jonathan R. Strosberg, MD, associate professor at H. Lee Moffitt Cancer Center, discusses pasireotide as a potential treatment for patients with neuroendocrine tumors.

Dr. Becerra on Ribociclib/Letrozole in ER+/HER2- Breast Cancer

July 20th 2016

Carlos Becerra, MD, physician, Texas Oncology, discusses a study examining the combination of ribociclib and letrozole in patients with ER-positive, HER2-negative advanced breast cancer.

Dr. Wakelee on Immunotherapy Versus Targeted Agents in NSCLC

July 20th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.

Dr. Pietrantonio on Nomogram to Predict Survival Rates in CRC

July 20th 2016

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses findings of a clinical trial examining a nomogram used to predict 12-week survival rates for patients with colorectal cancer (CRC).

Dr. Ilson on the Future Treatment Paradigm of Gastric Cancers

July 19th 2016

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the treatment paradigm of gastric cancers will evolve in the future.

Dr. Jakubowiak on Finding a Cure for Patients With Multiple Myeloma

July 19th 2016

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses the likelihood of finding a cure for patients with multiple myeloma.

CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

July 19th 2016

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

Dr. Federman on Use of Nanotechnology in Sarcomas

July 19th 2016

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the use of nanotechnology as a treatment for patients with sarcomas.

Dr. Rugo on SWISH Trial for HR-Positive Breast Cancer

July 18th 2016

Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Hellen Diller Family Comprehensive Cancer Center, discusses the results of the SWISH trial, which examined a dexamethasone-based mouthwash for the prevention of everolimus/exemestane stomatitis in postmenopausal women with hormone receptor (HR)-positive metastatic breast cancer.

Dr. Randy Sweis on Impact of Atezolizumab Approval in Bladder Cancer

July 15th 2016

Dr. Charles Ryan on Impact of IMAAGEN Trial in Nonmetastatic CRPC

July 15th 2016

Dr. Pal on Biomarker Development in Renal Cell Carcinoma

July 15th 2016

Sumanta Kumar Pal, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses biomarker development in the field of renal cell carcinoma (RCC).

Dr. Crawford on Ongoing Research With Radium-223 in mCRPC

July 15th 2016

E. David Crawford, MD, professor of Radiation Oncology, Department of Surgery, University of Colorado Denver, discusses ongoing research with radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Elizabeth Plimack on Nivolumab in Kidney Cancer

July 15th 2016